Peroxide-containing liposome as well as preparation method and application thereof

By preparing peroxide-containing liposomes, the iron ion transport function of DMT1 protein is enhanced, ferroptosis is induced, and the protein acts as a drug carrier, thus solving the problems of low sensitivity and drug resistance in existing tumor treatment methods and achieving effective tumor cell killing and synergistic therapeutic effects.

CN118986887AActive Publication Date: 2024-11-22SUZHOU UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411031578.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-22
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

Existing cancer treatment methods have drawbacks such as low sensitivity and easy development of drug resistance, and few existing ferroptosis initiators have been successfully applied in clinical practice.

Method used

A peroxide-containing liposome is provided, which is a spherical vesicle with a bilayer membrane structure formed by lipid molecules containing peroxide groups and carbon-carbon double bonds. It can induce ferroptosis by enhancing the iron ion transport function of DMT1 protein, and can also be used as a drug carrier to encapsulate other anti-tumor drugs for synergistic treatment.

Benefits of technology

This liposome can effectively kill tumor cells, reduce drug resistance, and significantly enhance anti-tumor effects through synergistic effects with other drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986887A_ABST
    Figure CN118986887A_ABST
Patent Text Reader

Abstract

The invention discloses a peroxide-containing liposome as well as a preparation method and application thereof, the peroxide-containing liposome is a spherical vesicle which is formed by lipid molecules containing one or more peroxide groups and has a double-layer membrane structure, and the lipid molecules contain carbon-carbon double bonds. The peroxide-containing liposome can be obtained by mixing peroxide-containing lipid molecules and a water-containing system, and the peroxide-containing lipid molecules are obtained by reacting unsaturated lipid molecules containing-CH = CH-and / or-C = C-with an additive in the presence of oxygen and a solvent, the additive is selected from one or more of lipoxygenase, an oxidation catalyst and an oxidizing agent. In-vitro cell and animal in-vivo experiments show that the peroxide-containing liposome can kill tumor cells, can be used as a sensitizer to cooperate with other tumor treatment modes, effectively improves the tumor treatment effect, and has a good application prospect in the anti-tumor aspect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biomedicine, and in particular to a peroxide-containing liposome and a preparation method and application thereof. Background Art

[0002] Traditional treatments (e.g., chemotherapy drugs, ionizing radiation) may help control and relieve local lesions, but may also cause cancer cells to evolve and become more resistant. The synergistic effect of ferroptosis and tumor therapy provides new treatment opportunities for refractory tumors. Ferroptosis is a type of cell death discovered in recent years that is closely related to the metabolism of iron, lipids, and amino acids. It has unique morphological, biochemical, and genetic changes that distinguish it from other forms of cell death. Therefore, the potential role of ferroptosis in tumor biology has been a research hotspot in recent years.

[0003] Since Stockwell et al. defined ferroptosis in 2012, eight different regulatory molecules have been identified, including system X. c - , glutathione peroxidase 4 (GPX4), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), coenzyme Q10 (CoQ10), ferroptosis inhibitory protein 1 (FSP1), lipoxygenases (LOXs), six transmembrane epithelial antigen of the prostate 3 (STEAP3), divalent metal ion transporter 1 (DMT1), labile iron pool, and lipid peroxides (LOOH). These ferroptosis indicators can be integrated into an integrated signaling network. The network consists of two braking axes, including system X c - / GSH / GPX4 and vitamin B5 / acetyl-CoA / HMG-CoA / CoQ10 / FSP1 for lipid peroxide degradation, as well as two driving axes involving lipid peroxide generation (PUFA / LOXs / LOOH) and iron metabolism (STEAP3 / DMT1 / Fe 2+ / LOOH). Among them, GPX4, FSP1 and system X in the brake axis c - found to play a key role in controlling ferroptosis. Chemical inhibitors targeting these proteins have been extensively studied as candidate ferroptosis initiators. For example, erastin and sulfasalazine were identified as System X c - Inhibitors of GPX4 include RSL3, FINO2, FIN56, and hexamethylmelamine, which can directly inhibit GPX4 activity; and statins (such as atorvastatin) which can indirectly reduce GPX4 activity by inhibiting HMG-CoA reductase. However, few of these drugs have been successfully used in clinical practice.

[0004] Traditional tumor treatment methods have disadvantages such as low sensitivity and easy acquisition of drug resistance; and few existing ferroptosis-initiating drugs have been successfully used in clinical practice. Therefore, there is an urgent need for a new type of tumor treatment drug that is safe, effective, and not prone to drug resistance. Summary of the invention

[0005] To solve the above problems, the present invention provides a peroxide-containing liposome and a preparation method and application thereof. The peroxide-containing liposome is a spherical vesicle with a double-layer membrane structure formed by lipid molecules containing one or more peroxide groups and carbon-carbon double bonds. It can induce ferroptosis of tumor cells and is not prone to drug resistance. It can also be used as a drug carrier to encapsulate other anti-tumor drugs for synergistic treatment, showing good synergistic therapeutic effects.

[0006] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0007] The first aspect of the present invention provides a peroxide-containing liposome, wherein the peroxide-containing liposome is a spherical vesicle with a double-layer membrane structure formed by lipid molecules containing one or more peroxide groups; the lipid molecules contain carbon-carbon double bonds.

[0008] Furthermore, the structure of the lipid molecule contains the following groups:

[0009]

[0010] A second aspect of the present invention provides a method for preparing peroxide-containing liposomes, comprising the following steps:

[0011] S1. reacting unsaturated lipid molecules with additives in the presence of oxygen and solvent to obtain lipid molecules containing peroxide groups; the unsaturated lipid molecules contain -CH=CH- and / or -C≡C-; the additives are selected from one or more of lipoxygenase, oxidation catalyst, and oxidant;

[0012] S2, mixing the lipid molecules containing peroxide groups prepared in S1 with an aqueous system to obtain the peroxide-containing liposomes.

[0013] Furthermore, in S1, the ratio of the molar amount of the unsaturated lipid molecules to the volume of the solvent is (1 μmol-1 mol): 1L; in some preferred embodiments, the unsaturated lipid molecules are 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-dilinoleoyl-sn-glycero-3-phospho-L-serine, 1,3-linoleic acid diglyceride or 1,2-dioleoyl phosphatidylcholine, but are not limited to the lipid molecule types listed above, and other unsaturated lipid molecules containing divalent groups CH=CH- and / or -C≡C- are applicable; the solvent is deionized water, physiological saline, PBS buffer solution or cell culture medium.

[0014] Furthermore, in S1, the oxidation catalyst includes but is not limited to one or more of MoS2 nanosheets, GO nanosheets (graphene oxide nanosheets), FeNGR nanosheets, and any oxidant with catalytic oxidation effect.

[0015] Furthermore, in S1, the oxidant includes but is not limited to cumene hydroperoxide and / or hydrogen peroxide.

[0016] Further, in S1, when the additive is lipoxygenase, the reaction concentration of the lipoxygenase is 1×10 4 -1×10 6 U / mL;

[0017] When the additive is an oxidation catalyst, the reaction concentration of the oxidation catalyst is 0.001-5 mg / mL;

[0018] When the additive is an oxidant, the reaction concentration of the oxidant is 1 μmol-1 mmol.

[0019] Furthermore, in S1, the reaction temperature is 4-300° C., and the reaction time is 0.1 hour-7 days.

[0020] Furthermore, in S1, unsaturated lipid molecules are first dispersed in a solvent to form a mixed solution, a lipid film is prepared by rotary evaporation, and then the solution is reacted with an additive in the presence of oxygen and a solvent to obtain lipid molecules containing peroxide groups.

[0021] Furthermore, in S2, the aqueous system includes but is not limited to deionized water, PBS buffer solution, cell culture medium, etc., such as RPMI 1640 culture medium.

[0022] Furthermore, in S2, the mixing treatment is preferably carried out by ultrasonic treatment, and the mixing treatment can also be carried out by stirring; the power of the ultrasonic treatment is preferably 10-100 W, and the time is 10-60 s.

[0023] The third aspect of the present invention provides an anti-tumor drug comprising the peroxide-containing liposome prepared by the preparation method described in the second aspect.

[0024] Furthermore, the anti-tumor drug is used to enhance the iron ion transport function of the DMT1 protein, thereby inducing ferroptosis to kill tumor cells.

[0025] Furthermore, the peroxide-containing liposomes are used as carriers to encapsulate active pharmaceutical ingredients. Preferably, the active pharmaceutical ingredients are used for anti-tumor, including but not limited to sulfasalazine, atorvastatin, artesunate, hexamethonium, etc.

[0026] Furthermore, the tumor includes but is not limited to human breast tumor cells MCF-7, mouse breast tumor cells 4T1, human or mouse melanoma cells A375, B16, etc.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] The present invention provides a peroxide-containing liposome, which is a spherical vesicle with a double-layer membrane structure formed by lipid molecules containing one or more peroxide groups and carbon-carbon double bonds. The present invention found through in vitro cell experiments that the peroxide-containing liposome can enhance the iron ion transport function of the lysosomal membrane DMT1 protein by post-modification, so that the Fe in tumor cells 2+ Redistribution triggers ferroptosis to kill tumor cells and is less likely to produce drug resistance.

[0029] The peroxide-containing liposomes provided by the present invention can be used as carriers to encapsulate other anti-tumor drugs. Through in vitro cell experiments and animal experiments, it is found that the peroxide-containing liposomes can be used as sensitizers or cooperate with other tumor treatment methods to achieve significant synergistic therapeutic effects, and have good application prospects in anti-tumor. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 is a flow chart for the preparation of peroxide-containing liposomes;

[0031] Figure 2 LC-MS graph of peroxide-containing liposomes and DLPC standard prepared in Example 1;

[0032] Figure 3 This is a cryo-electron micrograph of peroxide-containing liposomes;

[0033] Figure 4 This is a fluorescence probe detection diagram of BODIPY (581 / 591) containing peroxide liposomes;

[0034] Figure 5 This is a comparison of cell activity after MCF-7 cells were treated with different liposomes;

[0035] Figure 6 Figure 2 is a diagram showing the mechanism of action of peroxide-containing liposomes inducing ferroptosis, where A is FITC-labeled LIP PCPO Fluorescence images of co-localization of DMT1 protein and lysosomal DMT1 protein, B is LIP PCPO Mass spectra of DMT1 protein after interaction with DMT1 protein. C is the intracellular Fe 2+ fluorescence map of the distribution;

[0036] Figure 7 Docetaxel and peroxide-containing liposomes LIP PCPO IC for 4T1-R cells 50 Graph of changes over treatment time;

[0037] Figure 8 This is a graph showing the changes in tumor volume in breast cancer-bearing mice treated with different treatment methods. DETAILED DESCRIPTION

[0038] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0040] The sources of some of the reagents used in the following examples are as follows:

[0041] 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine (hereinafter referred to as PC, A:B = 18:2), 1,2-Dilinoleoyl-sn-glycero-3-phospho-L-serine (hereinafter referred to as PS, A:B = 18:2), 1,2-Dioleoylphosphatidylcholine (hereinafter referred to as DOPC, A:B = 18:1) and LOX enzyme were purchased from Sigma-Aldrich Inc.; 1,3-linoleic acid diglyceride (hereinafter referred to as DG, A:B = 18:2) was purchased from Cayman Chemical; BODIPY (581 / 591) fluorescent probe was purchased from ThermoFisher Scientific. A is the number of carbon atoms in a single carbon chain, and B is the number of unsaturated double bonds in a single carbon chain.

[0042] Example 1

[0043] This embodiment relates to peroxide-containing liposomes LIP PCPO The specific operation of synthesis is as follows:

[0044] Take 2.5 μL of MoS2 nanosheet material (5 mg / mL, concentration determined by ICP-OES method) dispersed in the aqueous phase, add 0.5 mL of 0.25 mg / mL 1,2-dilinoleoyl-tin-glyceryl-3-phosphocholine (PC) dispersion (the solvent is chloroform), incubate at 37°C with oxygen for 2 h, and after the reaction is completed, centrifuge at 20000g for 10 minutes, take the supernatant and use triple quadrupole liquid chromatography-mass spectrometry to detect and identify the reaction products, such as Figure 2 As shown, a peroxide group -OOH was successfully connected to PC to prepare the product PC-OOH, the product peak time was 10.2min, and the molecular weight was 814.5.

[0045] PC-OOH was dispersed in water and subjected to water bath ultrasound for 30 seconds to obtain peroxide-containing liposomes. The cryo-electron microscopy images of the prepared peroxide-containing liposomes are shown in Figure 2. Figure 3 As shown in the figure, it can be seen that spherical vesicles with a double-layer membrane structure are formed.

[0046] Example 2

[0047] This embodiment relates to peroxide-containing liposomes LIP PCPO 、LIP DGPO 、LIP PSPO The synthesis of Figure 1 As shown, the specific operations are as follows:

[0048] Measure 0.5 mL of 1 mg / mL PC, DG or PS solution (the solvent is chloroform) and place it in a 5 mL round-bottom flask; place the round-bottom flask on a rotary evaporator, and set the pressure, speed and temperature of the evaporator to 400 mbar, 80 rpm, and 25 °C, and remove the chloroform solvent by vacuuming. At this time, PC, DG or PS forms a uniform thin film on the inner wall of the round-bottom flask. Add 1 mL of 10 5 units LOX enzyme in RPMI 1640 solution; slowly introduce oxygen into the solution, heat it in an oil bath at a constant temperature of 37°C, and stir it at 300rpm to allow the LOX enzyme to catalyze the PC reaction for 4 hours. Then, ultrasonicate the round-bottom flask in a water bath for 20 seconds, and collect the reaction solution in a 2mL EP tube; finally, place the EP tube in a centrifuge and centrifuge it at 4°C and 20,000g for 10 minutes to remove the LOX enzyme. The supernatant in the EP tube is LIP. PCPO 、LIP DGPO or LIP PSPO , set aside. PCPO 、LIP DGPO and LIPPSPO All of them have a double-membrane spherical vesicle structure.

[0049] The peroxide-containing liposomes were analyzed using a liquid chromatography system coupled to a LTQXL mass spectrometer with an electrospray ionization (ESI) source. The MS data were collected and analyzed using Xcalibur software (Thermo Xcalibur 2.2). As shown in Table 1, a peroxide group -OOH was successfully attached to PC, DG or PS.

[0050] Table 1

[0051] Lipid molecules Retention time (min) m / z DG 15.4 634 DG-OOH 13.3 666 PC 13.5 782.5 PC-OOH 10.1 814.5 PS 9.5 784.7 PS-OOH 4.8 816.7

[0052] Example 3

[0053] This embodiment relates to peroxide-containing liposomes LIP DOPC The synthesis of lipid peroxides was investigated using BODIPY (581 / 591) fluorescent probe. Figure 1 As shown, the specific operations are as follows:

[0054] Measure 0.5 mL of 1 mg / mL DOPC solution (the solvent is chloroform) and place it in a 5 mL round-bottom flask; place the round-bottom flask on a rotary evaporator, and set the pressure, speed and temperature of the evaporator to 400 mbar, 80 rpm, 25 ° C, and remove the chloroform solvent by vacuum. At this time, DOPC forms a uniform film on the inner wall of the round-bottom flask. Add 1 mL of PBS buffer to the bottle, and ultrasonicate the round-bottom flask in a water bath for 20 seconds. The liquid is a DOPC liposome solution that does not contain peroxide. Collect the reaction solution in a 1.5 mL EP tube for later use. Take 500 μL of the above DOPC liposome solution to a 1.5 mL EP tube, add 8M H2O2, and incubate on a shaker at room temperature for 2 hours, then add 2 μL of 10 mM C11-BODIPY, and continue to incubate in the incubator away from light for 30 minutes. 100 μL per well was added to a 96-well black plate, and each sample was placed under a fluorescence microscope to observe the production of lipid peroxides at an excitation wavelength of 488 nm and an emission wavelength of 520 nm. Figure 4 As shown, DOPC liposomes can be oxidized by H2O2 to form peroxide-containing liposomes LIP DOPC .

[0055] Example 4

[0056] Taking the peroxide-containing liposomes prepared in Example 2 as an example, this example studies the killing effect of peroxide-containing liposomes on tumor cells. The unmodified liposomes prepared from PC, DG, and PS and the peroxide-containing liposomes prepared in Examples 2-4 were used to treat human breast cancer cell line MCF-7 (MCF-7R) cells, respectively. After 24 hours of treatment, the cell survival activity was detected by MTS assay. The specific operation is as follows:

[0057] will contain 5×10 3 100 μL of drug-resistant breast cancer cell suspension (MCF-7R) was added to a 96-well cell culture plate and incubated overnight in an incubator. After removing the supernatant, 100 μL of liposomes (LIP PC 、LIP DG 、LIP PS ) or liposomes containing peroxide (LIP PCPO 、LIP DGPO 、LIP PSPO ) RPMI 1640 medium or an equal amount of fresh medium was added to a 96-well plate. After incubation for 24 hours, the supernatant was removed, 120 μL MTS working solution was added to each well, and incubated in the dark for 2 hours; 100 μL MTS reaction solution was drawn from each well into another 96-well plate, and the optical density (OD) of the MTS reaction solution at a wavelength of 490 nm was detected using an ELISA reader. 490 Finally, the cell activity of each group was calculated using the following formula (1).

[0058]

[0059] Among them, OD T OD C and OD B Represent the OD of the treatment group, control group and MTS working solution itself 490 The test results are as follows: Figure 5 As shown in Figure 2, all unmodified liposomes had no effect on cell viability, while the three peroxide-containing liposomes significantly inhibited the proliferation of MCF-7R cells. PCPO The killing effect was the strongest in MCF-7R cells, reaching 80.33%.

[0060] Example 5

[0061] The peroxide-containing liposome LIP prepared in Example 2 PCPO For example, this example studies the mechanism of action of peroxide-containing liposomes on tumor cell killing, as follows:

[0062] (1) Observe the co-localization of lysosomal membrane DMT1 protein and FITC-labeled liposomes entering the cell using a fluorescence microscope. The specific operation is as follows:

[0063] MCF-7R cell suspension (20×10 4 100 μL of the supernatant was added to the confocal eight-well plate, and the plate was incubated overnight in the incubator. The supernatant was discarded and 100 μL of LIP containing 100 μM FITC was added to the plate. PCPO The solution was added to the experimental group. After 12 hours of incubation, the cells were rinsed three times with PBS solution. Then, 100 μL of 4% paraformaldehyde was added to each group of samples, and the cells were fixed for 20 minutes at room temperature. The paraformaldehyde fixative was removed and the cells were washed three times with PBS. 100 μL of PBS solution with a concentration of 0.3% Triton X-100 was added, and after incubation for 10 minutes, 3% BSA saline solution was added to the permeabilized cells and incubated at room temperature for 30 minutes. The supernatant was removed, and 100 μL of DMT1 antibody solution with a dilution ratio of 1:100 was added, and incubated overnight in a refrigerator at 4°C. After removing the primary antibody solution, the cells were rinsed three times with PBS solution, and then 100 μL of Cy3-labeled secondary antibody dilution (1:500) and Hoechst 33342 solution (10 μg / mL) were added, and incubated for 1 hour in the dark. After each sample was rinsed with PBS, the distribution of lysosomal membrane DMT1 protein (red) and liposomes (green) as well as their co-localization were observed under a scanning confocal microscope at excitation wavelengths of 594 nm and 488 nm, respectively.

[0064] Test results such as Figure 6 As shown in A, after incubation for 12 h, FITC-labeled LIP PCPO Co-localized with lysosomal DMT1 protein.

[0065] (2) Extracting lysosomal membrane DMT1 protein for gel electrophoresis separation, obtaining gel bands containing DMT1 protein for proteolysis, and performing proteomic analysis to further verify LIP PCPO The specific mechanism of action with DMT1 protein. The specific operations are as follows:

[0066] Add 2 mL of MCF-7R cell suspension (5×10 5 The wells were incubated overnight in an incubator. The supernatant was discarded and 2 mL of fresh RPMI 1640 medium or 2 mL of RPMI 1640 medium containing 100 μM LIP PCPOAn equal volume of RPMI 1640 culture medium solution was added to a 6-well plate. After continuing to culture the cells for 12 hours, the culture medium in the well plate was removed, the cells were scraped with a cell scraper, and the cells were collected in an EP tube by centrifugation. 150 μL of RIPA cell lysis solution containing 1% protease inhibitor was added to the EP tube, and it was placed in liquid nitrogen for 5 minutes, taken out and thawed by ultrasonication in a water bath, and repeated 5 times to fully lyse the cells; the EP tube was placed in a centrifuge, centrifuged at 20000g for 10 minutes, and the supernatant lysate of the EP tube was collected, and the protein concentration was determined using a BCA kit. Then, the Mini-PROTEAN Tetra system was used to add protein samples to a 10% SDS-PAGE gel, and the concentration voltage was set to 80V and the separation voltage was set to 120V. The protein samples were separated in Tris-glycine-SDS electrophoresis buffer. Finally, the gel containing the target band was cut out for protease digestion, and the digestion supernatant was collected for proteomics analysis.

[0067] Test results such as Figure 6 B shows LIP PCPO After interacting with the DMT1 protein, the DMT1 protein was chemically modified, specifically causing the amino acids in the DMT1 protein to form disulfide bonds at positions 245 and 248 and 334 and 365 as shown in the figure.

[0068] (3) LIP was further investigated using FeRhoNox-1 fluorescent reagent PCPO Intracellular Fe 2+ The specific operations are as follows:

[0069] Inoculate 0.1 mL of 20 × 10 4 MCF-7R suspension was added and placed in an incubator overnight. The culture medium was removed and 100 μM LIP was added to each well according to the grouping. PCPO 100 μL of 25 μM RSL3 culture medium solution was added and incubated for 12 h. The cells in each experimental group were rinsed three times with PBS buffer for 1 min each time. Finally, 200 μL of RPMI 1640 culture medium containing 10 μg / mL FeRhoNox-1 and 10 μg / mL Hoechst 33342 was added and incubated in the incubator for one hour in the dark. The supernatant was removed, and after rinsing with PBS, the ferrous ions (Fe 2+ ) distribution. Ammonium ferrous sulfate (Fe(NH4)2(SO4)2) was used as a positive control in the experiment.

[0070] The test results are as follows Figure 6 As shown in C, when the control group (Ctrl group) had Fe2+ When distributed in a dotted pattern, the peroxide-containing liposome LIP PCPO Make Fe 2+ It was diffusely distributed in cells, and its distribution pattern was similar to that of the positive control group (FAS group in the figure).

[0071] In summary, peroxide-containing liposomes LIP PCPO By post-modifying the lysosomal membrane DMT1 protein, its iron ion transport function is enhanced, allowing Fe 2+ Redistribution triggers ferroptosis to kill tumor cells.

[0072] Example 6

[0073] The peroxide-containing liposome LIP prepared in Example 2 PCPO For example, this example studies the drug resistance of peroxide-containing liposomes to tumor cells, and the specific operations are as follows:

[0074] The adriamycin-resistant mouse breast cancer cell 4T1-R cell suspension (1×10 5 Equal amounts of 100 mL / well were added to each well of a 6-well plate (2 mL / well) or a 24-well plate (0.5 mL / well) and incubated at 37°C for 24 hours. The cells were then exposed to 0.25×IC50 drug doses of docetaxel and peroxide-containing liposomes, respectively. After 24 hours, the cell density was assessed using an inverted microscope. When the cells adapted to the test concentration and showed >80% cell confluence, the exposure dose of docetaxel or peroxide-containing liposomes was increased. Otherwise, the exposure concentration was maintained for another 24 hours. After 60 days of continuous exposure, cells with evolved drug resistance were obtained.

[0075] The above test results are as follows Figure 7 As shown, peroxide-containing liposomes displayed sustained antitumor effects during long-term treatment and did not trigger the development of drug resistance in doxorubicin-resistant murine breast cancer cells.

[0076] Example 7

[0077] The peroxide-containing liposome LIP prepared in Example 2 PCPO For example, this example studies the encapsulation effect of peroxide-containing liposomes on different drugs (sulfasalazine (SSZ), atorvastatin (AT), artesunate (AS), hexamethonium (HMM)) and the killing effect of synergistic drugs on tumors. The details are as follows:

[0078] Sulfasalazine, atorvastatin, artesunate, and hexamethonium were dissolved in dimethyl sulfoxide at a drug concentration of 200 μM, respectively, and added to 500 μL of chloroform solution containing 120 μM unmodified liposomes and 80 μM peroxide-containing liposomes. The solvent was evaporated using a rotary evaporator (120 rpm) at room temperature to obtain a thin film in a round-bottom flask, which was then hydrated with 1 mL of deionized water. After ultrasonic treatment (40 W) in a water bath for 30 seconds and extrusion through an Avanti extruder equipped with a 0.1 μm polycarbonate membrane, free hydrophobic drugs were removed by centrifugation at 20,000 g for 10 minutes to obtain drug-encapsulated peroxide-containing liposomes. The drug-encapsulated peroxide-containing liposomes were then lyophilized using a vacuum centrifugal concentrator and dissolved in dimethyl sulfoxide or methanol for UV-visible spectroscopy detection. The encapsulation efficiency (EE) was calculated using the following formula:

[0079]

[0080] Among them, C L and C T are the concentration of hydrophobic drug encapsulated in liposomes and the total concentration of drug used in liposome encapsulation, respectively.

[0081] Human breast cancer cell line MCF-7 (MCF-7R) cells were treated with single drugs, peroxide-containing liposomes, and drugs encapsulated in peroxide-containing liposomes. After 24 hours of treatment, the cell survival activity was detected by MTS assay, and the combination index CI of peroxide-containing liposomes and different drugs was calculated. CI = AB / (A×B), where AB is the survival rate of tumor cells after treatment with drugs encapsulated in peroxide-containing liposomes, A is the survival rate of tumor cells after treatment with single drugs, and B is the survival rate of tumor cells after treatment with peroxide-containing liposomes. CI>1 indicates antagonism, CI=1 indicates additive effect, and CI<1 indicates synergistic effect.

[0082] The calculation results of the above encapsulation efficiency and combined index are shown in Table 2 below:

[0083] Table 2

[0084] Encapsulated Drugs Encapsulation rate (%) Combined Index <![CDATA[SSZ@LIP PCPO ]]> 36.44 0.19 <![CDATA[AT@LIP PCPO ]]> 68.38 0.25 <![CDATA[AS@LIP PCPO ]]> 36.56 0.10 <![CDATA[HMM@LIP PCPO ]]> 23.12 0.91

[0085] As shown in Table 2, the peroxide-containing liposomes can encapsulate different active pharmaceutical ingredients, and the encapsulation rate of atorvastatin can reach 68.38%. PCPO It exhibits synergistic effects with different drugs, among which peroxide-containing liposomes encapsulated with artesunate have the best synergistic killing effect on tumor cells.

[0086] Example 8

[0087] In this example, artesunate, peroxide-containing liposomes LIP PCPO and the peroxide-containing liposome LIP loaded with artesunate prepared in Example 6 PCPO They were used to treat breast cancer-bearing mice, and the specific operations were as follows:

[0088] Construction of breast cancer animal model: 1) 100 μL 5% chloral hydrate saline solution was injected intraperitoneally to anesthetize BALB / c female mice; 2) 80 μL cell suspension (4T1-R, 5×10 5 3) The anesthetized mice were resuscitated on a 37°C constant temperature heating pad and returned to the cage for maintenance.

[0089] Administration: Tail vein injection, three times a week. Among them, the control group was 100 μL normal saline (n=5); the artesunate group (11.7 mg / kg, n=5); the peroxide-containing liposome group (100 mg / kg, n=5); the peroxide-containing liposome group encapsulating artesunate (AS) (111.7 mg / kg, n=5).

[0090] After receiving the corresponding treatment, the length (L) and width (W) of the tumor were measured with a vernier caliper every 3 days, and the tumor volume was calculated according to the following formula:

[0091]

[0092] Tumor growth curves of mice treated with different treatment methods are shown in Figure 2. Figure 8 As shown in the figure, it can be seen that peroxide-containing liposomes and peroxide-containing liposomes encapsulated with artesunate can significantly inhibit tumor growth, wherein the combined treatment makes the tumor size 2.5 times smaller than that of the unmodified liposome control group (AS), showing a significant synergistic therapeutic effect.

[0093] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. A peroxide-containing liposome, characterized in that: A spherical vesicle with a double-layer membrane structure formed by lipid molecules containing one or more peroxide groups; the lipid molecules contain carbon-carbon double bonds.

2. The peroxide-containing liposome according to claim 1, wherein The structure of the lipid molecule contains the following groups:

3. A method for preparing peroxide-containing liposomes according to claim 1 or 2, characterized in that: The following steps are involved: S1. reacting unsaturated lipid molecules with an additive in the presence of oxygen and a solvent to obtain lipid molecules containing peroxide groups; the unsaturated lipid molecules contain -CH=CH- and / or -C≡C-; the additive is selected from one or more of lipoxygenase, an oxidation catalyst, and an oxidant; S2. Mixing the lipid molecules containing peroxide groups prepared in S1 with an aqueous system to obtain the peroxide-containing liposomes.

4. The preparation method according to claim 3, characterized in that In S1, the ratio of the molar amount of the unsaturated lipid molecules to the volume of the solvent is (1 μmol-1 mol):1L; The unsaturated lipid molecule is 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-dilinoleoyl-sn-glycero-3-phospho-L-serine, 1,3-linoleic acid diglyceride or 1,2-dioleoyl phosphatidylcholine; The solvent is deionized water, physiological saline, PBS buffer solution or cell culture medium.

5. The preparation method according to claim 3, characterized in that In S1, the oxidation catalyst is selected from one or more of MoS2 nanosheets, GO nanosheets, and Fe / N co-doped graphene nanosheets; The oxidant is cumene hydroperoxide and / or hydrogen peroxide.

6. The preparation method according to claim 3, characterized in that In S1, when the additive is lipoxygenase, the reaction concentration of the lipoxygenase is 1×10 4 -1×10 6 U / mL; When the additive is an oxidation catalyst, the reaction concentration of the oxidation catalyst is 0.001-5 mg / mL; When the additive is an oxidant, the reaction concentration of the oxidant is 1 μM-1 mM.

7. The preparation method according to claim 3, characterized in that In S1, the reaction temperature is 4-300° C., and the reaction time is 0.1 hour to 7 days.

8. The preparation method according to claim 3, characterized in that In S2, the mixing treatment is carried out by ultrasonic treatment; the power of the ultrasonic treatment is 10-100 W, and the time is 10-60 s.

9. An anti-tumor drug, characterized in that: The invention comprises the peroxide-containing liposome according to claim 1 or 2, or the peroxide-containing liposome prepared by the preparation method according to any one of claims 3 to 8.

10. The antitumor drug according to claim 9, characterized in that The peroxide-containing liposome is used as a carrier to encapsulate the active pharmaceutical ingredient.

Citation Information

Patent Citations

  • Lipid peroxide generator and preparation method and application of lipidosome

    CN110354079A

  • Modified iron-based nano material, iron-based nano liposome and anti-tumor application of modified iron-based nano material and iron-based nano liposome

    CN114848840A

  • Oxidized liposome for efficiently inducing ferroptosis of tumor cells as well as preparation method and application of oxidized liposome

    CN115252779A

  • Liposome enzyme nanoreactor, preparation method and application of liposome enzyme nanoreactor in anti-tumor treatment

    CN116172958A

  • Lipid nano regulator for sensitizing ferroptosis as well as preparation method and application of lipid nano regulator

    CN118203670A